エドガーで原本を確認する
☒ Form 20-F
|
☐ Form 40-F
|
UNILEVER PLC |
|||
Date: 28 July 2026 |
By: |
/s/ P. Kakkad
|
|
Name
:
|
P. Kakkad |
||
Title: |
Chief Legal Officer and Group Company Secretary
|
||
First Half Key Highlights |
First Half Key Figures |
Underlying performance |
GAAP measures |
||||||
(unaudited) |
2026 |
vs 2025(b)
|
2026 |
vs 2025(b)
|
|||
First Half |
|||||||
Underlying sales growth (USG) |
4.8% |
Turnover |
€25.6bn |
0.5% |
|||
Beauty & Wellbeing |
5.9% |
Beauty & Wellbeing |
€6.5bn |
0.3% |
|||
Personal Care |
4.8% |
Personal Care |
€6.8bn |
4.2% |
|||
Home Care |
7.6% |
Home Care |
€6.0bn |
1.5% |
|||
Foods |
1.2% |
Foods |
€6.3bn |
(4.0)% |
|||
Underlying operating profit |
€5.2bn |
0.9% |
Operating profit |
€4.9bn |
2.6% |
||
Underlying operating margin |
20.3% |
10bps |
Operating margin |
19.1% |
40bps |
||
Underlying earnings per share |
€1.61 |
2.4% |
Diluted earnings per share |
€1.38 |
(2.5)% |
||
Free cash flow |
€1.5bn |
€0.5bn |
Net profit |
€3.3bn |
(3.5)% |
||
Second Quarter |
|||||||
USG |
5.8% |
Turnover |
€13.0bn |
3.8% |
|||
Quarterly dividend payable in September 2026 (a)
|
€0.4664 |
per share(b)
|
|||||
Chief Executive Officer Statement |
Outlook |
First Half Review: Unilever Group |
(unaudited) |
Turnover |
USG |
UVG |
UPG |
A&D |
Currency |
Turnover
change
|
First Half |
€25.6bn |
4.8% |
4.2% |
0.6% |
0.7% |
(4.9)% |
0.5% |
Second Quarter |
€13.0bn |
5.8% |
5.5% |
0.2% |
0.6% |
(2.4)% |
3.8% |
First Half Review: Unilever Group (continued)
|
(unaudited) |
UOP |
UOP
growth
|
UOM% |
Change in
UOM
|
OP |
OP growth |
OM% |
Change in
OM
|
First Half |
€5.2bn |
0.9% |
20.3% |
10bps |
€4.9bn |
2.6% |
19.1% |
40bps |
First Half Review: Unilever Group (continued)
|
Conference Call |
Upcoming Events |
Date |
Events |
4 September 2026 |
Hindustan Unilever Investor Event 2026 (Mumbai, India) |
28 October 2026 |
Q3 2026 Trading Statement |
4 November 2026 |
Unilever Investor Event 2026 (New York, USA) |
First Half Review: Business Groups |
First Half 2026
|
Second Quarter 2026
|
|||||||||
(unaudited) |
Turnover |
USG |
UVG |
UPG |
UOM |
Change
in UOM
|
Turnover |
USG |
UVG |
UPG |
Unilever |
€25.6bn |
4.8% |
4.2% |
0.6% |
20.3% |
10bps |
€13.0bn |
5.8% |
5.5% |
0.2% |
Beauty & Wellbeing |
€6.5bn |
5.9% |
4.5% |
1.3% |
19.5% |
10bps |
€3.4bn |
8.1% |
6.9% |
1.1% |
Personal Care |
€6.8bn |
4.8% |
4.1% |
0.7% |
22.2% |
10bps |
€3.5bn |
5.9% |
6.8% |
(0.9)% |
Home Care |
€6.0bn |
7.6% |
7.4% |
0.2% |
15.8% |
30bps |
€3.0bn |
9.1% |
8.6% |
0.5% |
Foods |
€6.3bn |
1.2% |
1.2% |
—% |
23.3% |
0bps |
€3.1bn |
0.2% |
(0.1)% |
0.2% |
(unaudited) |
Turnover |
USG |
UVG |
UPG |
A&D |
Currency |
Turnover
change
|
UOM% |
Change
in UOM
|
First Half |
€6.5bn |
5.9% |
4.5% |
1.3% |
0.8% |
(6.0)% |
0.3% |
19.5% |
10bps |
Second Quarter |
€3.4bn |
8.1% |
6.9% |
1.1% |
1.0% |
(3.2)% |
5.7% |
First Half Review: Business Groups (continued)
|
(unaudited) |
Turnover |
USG |
UVG |
UPG |
A&D |
Currency |
Turnover
change
|
UOM% |
Change
in UOM
|
First Half |
€6.8bn |
4.8% |
4.1% |
0.7% |
4.0% |
(4.5)% |
4.2% |
22.2% |
10bps |
Second Quarter |
€3.5bn |
5.9% |
6.8% |
(0.9)% |
3.3% |
(2.0)% |
7.3% |
(unaudited) |
Turnover |
USG |
UVG |
UPG |
A&D |
Currency |
Turnover
change
|
UOM% |
Change
in UOM
|
First Half |
€6.0bn |
7.6% |
7.4% |
0.2% |
(0.5)% |
(5.2)% |
1.5% |
15.8% |
30bps |
Second Quarter |
€3.0bn |
9.1% |
8.6% |
0.5% |
(0.7)% |
(3.0)% |
5.0% |
First Half Review: Business Groups (continued)
|
(unaudited) |
Turnover |
USG |
UVG |
UPG |
A&D |
Currency |
Turnover
change
|
UOM% |
Change
in UOM
|
First Half |
€6.3bn |
1.2% |
1.2% |
—% |
(1.5)% |
(3.7)% |
(4.0)% |
23.3% |
0bps |
Second Quarter |
€3.1bn |
0.2% |
(0.1)% |
0.2% |
(1.4)% |
(1.5)% |
(2.7)% |
First Half Review: Geographical Areas |
First Half 2026
|
Second Quarter 2026
|
|||||||
(unaudited) |
Turnover |
USG |
UVG |
UPG |
Turnover |
USG |
UVG |
UPG |
Unilever |
€25.6bn |
4.8% |
4.2% |
0.6% |
€13.0bn |
5.8% |
5.5% |
0.2% |
Asia Pacific Africa |
€11.3bn |
7.3% |
6.1% |
1.2% |
€5.7bn |
8.8% |
7.2% |
1.5% |
The Americas |
€9.7bn |
4.6% |
4.2% |
0.4% |
€5.1bn |
5.7% |
6.2% |
(0.5)% |
Europe |
€4.6bn |
(0.9)% |
(0.2)% |
(0.6)% |
€2.2bn |
(1.3)% |
0.3% |
(1.6)% |
First Half 2026
|
Second Quarter 2026
|
|||||||
(unaudited) |
Turnover |
USG |
UVG |
UPG |
Turnover |
USG |
UVG |
UPG |
Emerging markets |
€15.4bn |
7.0% |
5.8% |
1.2% |
€7.8bn |
8.3% |
7.4% |
0.9% |
Developed markets |
€10.2bn |
1.5% |
1.9% |
(0.4)% |
€5.2bn |
2.0% |
2.8% |
(0.8)% |
North America |
€5.7bn |
2.7% |
3.2% |
(0.5)% |
€3.0bn |
3.6% |
4.4% |
(0.9)% |
Latin America |
€4.0bn |
7.6% |
5.7% |
1.7% |
€2.1bn |
8.9% |
8.8% |
0.1% |
First Half Review: Geographical Areas (continued)
|
Additional commentary on the financial statements - First Half |
Additional commentary on the financial statements - First Half (continued)
|
Non-GAAP measures |
Half year
average rate
in 2026
|
Half year
average rate
in 2025
|
|
Brazilian real (€1 = BRL) |
6.013 |
6.281 |
Chinese yuan (€1 = CNY) |
8.015 |
7.895 |
Indian rupee (€1 = INR) |
108.565 |
93.749 |
Indonesia rupiah (€1 = IDR) |
20,046 |
17,874 |
Mexican peso (€1 = MXN) |
20.414 |
21.788 |
Philippine peso (€1 = PHP) |
69.928 |
62.192 |
Turkish lira (€1 = TRY) |
52.003 |
40.649 |
UK pound sterling (€1 = GBP) |
0.868 |
0.842 |
US dollar (€1 = US$) |
1.167 |
1.088 |
Non-GAAP measures (continued)
|
(unaudited) |
Beauty &
Wellbeing
|
Personal
Care
|
Home Care |
Foods |
Total |
Second Quarter |
|||||
Turnover (€ million) |
|||||
2025 |
3,219 |
3,296 |
2,865 |
3,187 |
12,567 |
2026 |
3,403 |
3,535 |
3,009 |
3,099 |
13,046 |
Turnover growth (%) |
5.7 |
7.3 |
5.0 |
(2.7) |
3.8 |
Effect of acquisitions (%) |
1.1 |
3.4 |
– |
– |
1.2 |
Effect of disposals (%) |
(0.2) |
– |
(0.7) |
(1.4) |
(0.6) |
Effect of currency-related items (%), of which: |
(3.2) |
(2.0) |
(3.0) |
(1.5) |
(2.4) |
Exchange rates changes (%) |
(3.5) |
(2.4) |
(3.6) |
(1.7) |
(2.8) |
Extreme price growth in hyperinflationary markets* (%) |
0.3 |
0.4 |
0.6 |
0.2 |
0.4 |
Underlying sales growth (%) |
8.1 |
5.9 |
9.1 |
0.2 |
5.8 |
First Half |
|||||
Turnover (€ million) |
|||||
2025 |
6,489 |
6,545 |
5,904 |
6,568 |
25,506 |
2026 |
6,509 |
6,817 |
5,992 |
6,305 |
25,623 |
Turnover growth (%) |
0.3 |
4.2 |
1.5 |
(4.0) |
0.5 |
Effect of acquisitions (%) |
0.9 |
4.0 |
– |
– |
1.3 |
Effect of disposals (%) |
(0.2) |
– |
(0.5) |
(1.5) |
(0.5) |
Effect of currency-related items (%), of which: |
(6.0) |
(4.5) |
(5.2) |
(3.7) |
(4.9) |
Exchange rates changes (%) |
(6.2) |
(4.9) |
(5.7) |
(3.9) |
(5.1) |
Extreme price growth in hyperinflationary markets* (%) |
0.2 |
0.4 |
0.5 |
0.2 |
0.3 |
Underlying sales growth (%) |
5.9 |
4.8 |
7.6 |
1.2 |
4.8 |
(unaudited) |
Asia Pacific
Africa
|
The
Americas
|
Europe |
Total |
Second Quarter |
||||
Turnover (€ million) |
||||
2025 |
5,531 |
4,680 |
2,356 |
12,567 |
2026 |
5,694 |
5,067 |
2,285 |
13,046 |
Turnover growth (%) |
2.9 |
8.3 |
(3.0) |
3.8 |
Effect of acquisitions (%) |
0.1 |
3.1 |
– |
1.2 |
Effect of disposals (%) |
(0.2) |
(0.6) |
(1.4) |
(0.6) |
Effect of currency-related items (%), of which: |
(5.2) |
– |
(0.4) |
(2.4) |
Exchange rates changes (%) |
(5.8) |
(0.3) |
(0.4) |
(2.8) |
Extreme price growth in hyperinflationary markets* (%) |
0.6 |
0.3 |
– |
0.4 |
Underlying sales growth (%) |
8.8 |
5.7 |
(1.3) |
5.8 |
First Half |
||||
Turnover (€ million) |
||||
2025 |
11,400 |
9,424 |
4,682 |
25,506 |
2026 |
11,298 |
9,756 |
4,569 |
25,623 |
Turnover growth (%) |
(0.9) |
3.5 |
(2.4) |
0.5 |
Effect of acquisitions (%) |
0.2 |
3.0 |
0.5 |
1.3 |
Effect of disposals (%) |
(0.2) |
(0.4) |
(1.6) |
(0.5) |
Effect of currency-related items (%), of which: |
(7.7) |
(3.5) |
(0.4) |
(4.9) |
Exchange rates changes (%) |
(8.2) |
(3.7) |
(0.4) |
(5.1) |
Extreme price growth in hyperinflationary markets* (%) |
0.5 |
0.3 |
– |
0.3 |
Underlying sales growth (%) |
7.3 |
4.6 |
(0.9) |
4.8 |
Non-GAAP measures (continued)
|
Non-GAAP measures (continued)
|
€ million |
First Half |
|
(unaudited) |
2026 |
2025(f)
|
Non-underlying items within operating profit before tax |
(308) |
(386) |
Acquisition and disposal-related costs(a)
|
(180) |
(117) |
Gain on disposal of group companies(b)
|
70 |
47 |
Restructuring costs(c)
|
(131) |
(265) |
Impairments |
(13) |
(42) |
Other(d)
|
(54) |
(9) |
Tax on non-underlying items within operating profit |
10 |
81 |
Non-underlying items within operating profit after tax |
(298) |
(305) |
Non-underlying items not in operating profit but within net profit before tax |
(85) |
(25) |
Net monetary loss arising from hyperinflationary economies |
(85) |
(25) |
Tax impact of non-underlying items not in operating profit but within net profit, including
non-underlying tax items(e)
|
(99) |
(5) |
Non-underlying items not in operating profit but within net profit after tax |
(184) |
(30) |
Non-underlying items after tax |
(482) |
(335) |
Attributable to: |
||
Non-controlling interests |
2 |
(9) |
Shareholders’ equity |
(484) |
(326) |
€ million |
First Half |
|
(unaudited) |
2026 |
2025(a)
|
Operating profit |
4,885 |
4,762 |
Non-underlying items within operating profit |
308 |
386 |
Underlying operating profit |
5,193 |
5,148 |
Turnover |
25,623 |
25,506 |
Operating margin (%) |
19.1 |
18.7 |
Underlying operating margin (%) |
20.3 |
20.2 |
Non-GAAP measures (continued)
|
€ million |
First Half |
|
(unaudited) |
2026 |
2025(a)
|
Taxation |
1,368 |
1,164 |
Tax impact of: |
||
Non-underlying items within operating profit |
10 |
81 |
Non-underlying items not in operating profit but within net profit |
(99) |
(5) |
Taxation before tax impact of non-underlying items |
1,279 |
1,240 |
Profit before taxation |
4,659 |
4,575 |
Share of net profit of joint ventures and associates |
(140) |
(146) |
Profit before tax excluding share of net profit of joint ventures and associates |
4,519 |
4,429 |
Non-underlying items within operating profit before tax |
308 |
386 |
Non-underlying items not in operating profit but within net profit before tax |
85 |
25 |
Profit before tax excluding non-underlying items before tax and share of net profit of
joint ventures and associates
|
4,912 |
4,840 |
Effective tax rate (%) |
30.3 |
26.3 |
Underlying effective tax rate (%) |
26.0 |
25.6 |
€ million |
First Half |
|
(unaudited) |
2026 |
2025(a)
|
Net profit |
3,291 |
3,411 |
Non-controlling interest |
(267) |
(286) |
Net profit attributable to shareholders’ equity - used for basic and diluted earnings per
share
|
3,024 |
3,125 |
Post-tax impact of non-underlying items attributable to shareholders’ equity |
484 |
326 |
Underlying profit attributable to shareholders’ equity - used for basic and diluted
earnings per share
|
3,508 |
3,451 |
Diluted average number of shares (millions of share units) |
2,183 |
2,200 |
Diluted EPS (€) |
1.38 |
1.42 |
Underlying EPS – diluted (€) |
1.61 |
1.57 |
Non-GAAP measures (continued)
|
€ million |
As at 30 June
2026
|
As at 31
December
2025
|
As at 30 June
2025
|
(unaudited) | |||
Total financial liabilities |
(32,110) |
(28,278) |
(32,025) |
Current financial liabilities |
(8,142) |
(2,582) |
(7,155) |
Non-current financial liabilities |
(23,968) |
(25,696) |
(24,870) |
Cash and cash equivalents as per balance sheet |
4,726 |
3,941 |
4,344 |
Cash and cash equivalents as per cash flow statement |
4,671 |
3,870 |
4,268 |
Add: bank overdrafts deducted therein |
55 |
65 |
70 |
Less: cash and cash equivalents held for sale |
– |
6 |
6 |
Other current financial assets |
1,322 |
1,121 |
1,123 |
Non-current financial asset derivatives that relate to financial
liabilities
|
101 |
140 |
203 |
Net debt |
(25,961) |
(23,076) |
(26,355) |
€ million |
First Half |
|
(unaudited) |
2026 |
2025(a)
|
Net profit from continuing operations |
3,291 |
3,411 |
Net finance costs |
302 |
277 |
Net monetary loss arising from hyperinflationary economies |
85 |
25 |
Share of net profit of joint ventures and associates |
(140) |
(146) |
Other loss/(income) from non-current investments and associates |
(21) |
31 |
Taxation |
1,368 |
1,164 |
Operating profit |
4,885 |
4,762 |
Depreciation and amortisation |
619 |
604 |
Earnings before interest, taxes, depreciation and amortisation (EBITDA) |
5,504 |
5,366 |
Non-underlying items within operating profit |
308 |
386 |
Underlying earnings before interest, taxes, depreciation and amortisation (UEBITDA) |
5,812 |
5,752 |
Non-GAAP measures (continued)
|
|
€ million |
First Half |
|
(unaudited) |
2026 |
2025(a)
|
Cash flow from operating activities |
4,347 |
3,147 |
Income tax paid |
(1,770) |
(1,128) |
Net capital expenditure |
(599) |
(480) |
Net interest paid |
(429) |
(455) |
Free cash flow |
1,549 |
1,084 |
Net cash flow used in investing activities |
(1,040) |
(527) |
Net cash flow used in financing activities |
(1,186) |
(3,045) |
Other Information |
Principal Risk Factors |
Cautionary Statement |
Directors' Responsibility Statement |
Enquiries |
Media: Media Relations Team
|
Investors: Investor Relations Team
|
||
UK |
+44 77 4249 0136 |
press-office.london@unilever.com |
investor.relations@unilever.com |
or |
+44 77 7999 9683 |
jonathan.sibun@teneo.com |
|
NL |
+31 63 029 6394 |
willemijn.storimans@unilever.com |
|
or |
+31 61 500 8293 |
fleur-van.bruggen@unilever.com |
|
Consolidated income statement |
€ million |
First Half |
||
(unaudited) |
2026 |
2025(a)
|
Change |
Turnover |
0.5% |
||
Operating profit |
2.6% |
||
Net finance costs |
( |
( |
|
Pensions and similar obligations |
|||
Finance income |
|||
Finance costs |
( |
( |
|
Net monetary loss arising from hyperinflationary economies |
( |
( |
|
Share of net profit of joint ventures and associates |
|||
Other income (loss) from non-current investments and associates |
( |
||
Profit before taxation |
1.8% |
||
Taxation |
( |
( |
|
Net profit from continuing operations |
(3.5)% |
||
Profit after taxation from discontinued operations |
( |
||
Gain on disposal of discontinued operations |
|||
Net profit from discontinued operations |
|||
Total net profit |
|||
Attributable to: |
|||
Non-controlling interests |
|||
Shareholders’ equity |
(5.6)% |
||
Total profit attributable to shareholders’ equity arises from: |
|||
Continuing operations |
|||
Discontinued operations |
|||
Total profit attributable to non-controlling interests arises from: |
|||
Continuing operations |
|||
Discontinued operations |
( |
||
Earnings per share |
|||
Basic earnings per share (euros) |
(5.0)% |
||
Basic earnings per share (€) from continuing operations |
(2.6)% |
||
Basic earnings per share (€) from discontinued operations |
(24.1)% |
||
Diluted earnings per share (euros) |
(4.9)% |
||
Diluted earnings per share (€) from continuing operations |
(2.5)% |
||
Diluted earnings per share (€) from discontinued operations |
(24.0)% |
Consolidated statement of comprehensive income |
€ million |
First Half |
|
(unaudited) |
2026 |
2025(a)
|
Net profit |
||
Other comprehensive income from continuing operations |
||
Items that will not be reclassified to profit or loss, net of tax: |
||
Gains/(losses) on equity instruments measured at fair value through other
comprehensive income
|
( |
|
Remeasurement of defined benefit pension plans |
( |
|
Items that may be reclassified subsequently to profit or loss, net of tax: |
||
Gains/(losses) on cash flow hedges |
( |
|
Currency retranslation gains/(losses) |
( |
|
Total comprehensive income from continuing operations |
( |
|
Other comprehensive income from discontinued operations |
( |
|
Total comprehensive income |
||
Attributable to: |
||
Non-controlling interests |
||
Shareholders’ equity |
||
Consolidated statement of changes in equity |
(unaudited) |
||||||||
€ million |
Called
up share
capital
|
Share
premium
account
|
Unification
reserve
|
Other
reserves
|
Retained
profit
|
Total |
Non-
controlling
interest
|
Total
equity
|
First half - 2026
|
||||||||
1 January 2026 |
( |
( |
||||||
Profit or loss for the period |
– |
– |
– |
– |
||||
Other comprehensive income, net of tax: |
||||||||
Equity instruments (losses)/gains |
– |
– |
– |
– |
– |
|||
Cash flow hedges (losses)gains |
– |
– |
– |
– |
||||
Remeasurements of defined benefit
pension plans
|
– |
– |
– |
– |
– |
|||
Currency retranslation (losses)/
gains(a)
|
– |
– |
– |
( |
||||
Total comprehensive income |
– |
– |
– |
|||||
Dividends on ordinary capital |
– |
– |
– |
– |
( |
( |
– |
( |
Repurchase of shares(b)
|
– |
– |
– |
( |
– |
( |
– |
( |
Movements in treasury shares(c)
|
– |
– |
– |
– |
( |
( |
– |
( |
Share-based payment credit(d)
|
– |
– |
– |
– |
– |
|||
Dividends paid to non-controlling
interests
|
– |
– |
– |
– |
– |
– |
( |
( |
Hedging loss/(gain) transferred to non-
financial assets
|
– |
– |
– |
( |
– |
( |
( |
( |
Other movements in equity(f)
|
– |
– |
– |
( |
( |
( |
||
30 June 2026 |
( |
( |
||||||
First half - 2025
|
||||||||
1 January 2025 |
( |
( |
||||||
Profit or loss for the period |
– |
– |
– |
– |
||||
Other comprehensive income, net of tax: |
||||||||
Equity instruments gains/(losses) |
– |
– |
– |
( |
– |
( |
– |
( |
Cash flow hedges gains/(losses) |
– |
– |
– |
( |
– |
( |
( |
( |
Remeasurements of defined benefit
pension plans
|
– |
– |
– |
– |
( |
( |
( |
( |
Currency retranslation gains/
(losses)(a)
|
– |
– |
– |
( |
( |
( |
( |
( |
Total comprehensive income |
– |
– |
– |
( |
||||
Dividends on ordinary capital |
– |
– |
– |
– |
( |
( |
– |
( |
Repurchase of shares(b)
|
– |
– |
– |
( |
– |
( |
– |
( |
Movements in treasury shares(c)
|
– |
– |
– |
( |
( |
– |
( |
|
Share-based payment credit(d)
|
– |
– |
– |
– |
– |
|||
Dividends paid to non-controlling
interests
|
– |
– |
– |
– |
– |
– |
( |
( |
Hedging loss/(gain) transferred to non-
financial assets
|
– |
– |
– |
( |
– |
( |
( |
|
Other movements in equity(e)
|
– |
– |
– |
( |
( |
( |
||
30 June 2025 |
( |
( |
Consolidated balance sheet |
(unaudited) |
|||
€ million |
As at 30 June
2026
|
As at 31
December
2025
|
As at 30 June
2025
|
Non-current assets |
|||
Goodwill |
|||
Intangible assets |
|||
Property, plant and equipment |
|||
Pension asset for funded schemes in surplus |
|||
Deferred tax assets |
|||
Financial assets |
|||
Other non-current assets |
|||
Current assets |
|||
Inventories |
|||
Trade and other current receivables |
|||
Current tax assets |
|||
Cash and cash equivalents |
|||
Other financial assets |
|||
Assets held for sale |
|||
Total assets |
|||
Current liabilities |
|||
Financial liabilities |
|||
Trade payables and other current liabilities |
|||
Current tax liabilities |
|||
Provisions |
|||
Liabilities held for sale |
|||
Non-current liabilities |
|||
Financial liabilities |
|||
Non-current tax liabilities |
|||
Pensions and post-retirement healthcare liabilities: |
|||
Funded schemes in deficit |
|||
Unfunded schemes |
|||
Provisions |
|||
Deferred tax liabilities |
|||
Other non-current liabilities |
|||
Total liabilities |
|||
Equity |
|||
Shareholders’ equity |
|||
Non-controlling interests |
|||
Total equity |
|||
Total liabilities and equity |
Consolidated cash flow statement |
(unaudited) |
First Half |
|
€ million |
2026 |
2025(a)
|
Net profit from continuing operations |
||
Taxation |
||
Share of net profit of joint ventures/associates and other (income)/loss from non-current
investments and associates
|
( |
( |
Net monetary loss arising from hyperinflationary economies |
||
Net finance costs |
||
Operating profit from continuing operations |
||
Depreciation, amortisation and impairment |
||
Changes in working capital |
( |
( |
Inventories |
( |
( |
Trade and other receivables (b)
|
( |
( |
Trade payables and other liabilities (b)
|
( |
|
Pensions and similar obligations less payments |
||
Provisions less payments |
( |
( |
Elimination of loss/(profits) on disposals |
( |
( |
Non-cash charge for share-based compensation |
||
Other adjustments |
||
Cash flow from continuing operating activities |
||
Income tax paid on continuing operations |
( |
( |
Net cash flow from continuing operating activities |
||
Cash flow from operations attributable to discontinued operations |
( |
|
Income tax paid from discontinued operation |
( |
|
Net cash flow from discontinued operating activities |
( |
|
Total cash flows from operating activities |
||
Interest received |
||
Purchase of intangible assets |
( |
( |
Purchase of property, plant and equipment |
( |
( |
Disposal of property, plant and equipment |
||
Acquisition of businesses and investments in joint ventures and associates |
( |
( |
Disposal of businesses, joint ventures and associates |
||
Acquisition of other non-current investments |
( |
( |
Disposal of other non-current investments |
||
Dividends from joint ventures, associates and other non-current investments |
||
Sale/(purchase) of financial assets |
( |
|
Net cash flow used in continuing investing activities |
( |
( |
Net cash investing cash flows attributable to discontinued operations |
( |
|
Total net cash (outflow)/inflow from investing activities |
( |
( |
Dividends paid on ordinary share capital |
( |
( |
Interest paid |
( |
( |
Net change in short-term borrowings |
||
Additional financial liabilities |
||
Repayment of financial liabilities |
( |
( |
Capital element of lease rental payments |
( |
( |
Repurchase of shares |
( |
( |
Other financing activities (c)
|
( |
( |
Net cash flow used in continuing financing activities |
( |
( |
Net cash flow from discontinued financing activities |
||
Total net cash flow used in financing activities |
( |
( |
Net increase/(decrease) in cash and cash equivalents |
( |
|
Cash and cash equivalents at the beginning of the period |
||
Effect of foreign exchange rate changes |
( |
|
Cash and cash equivalents at the end of the period |
||
Notes to the condensed consolidated financial statements |
1.Accounting information and policies
|
Notes to the condensed consolidated financial statements |
2.Segment information - Business Groups
|
Second Quarter |
Beauty &
Wellbeing
|
Personal
Care
|
Home
Care
|
Foods |
Total |
Turnover (€ million) |
|||||
2025 |
|||||
2026 |
|||||
Change (%) |
( |
First Half |
Beauty &
Wellbeing
|
Personal
Care
|
Home Care |
Foods |
Total |
Turnover (€ million) |
|||||
2025 |
|||||
2026 |
|||||
Change (%) |
( |
||||
Operating profit (€ million) |
|||||
2025 |
|||||
2026 |
|||||
Underlying operating profit (€ million) |
|||||
2025 |
|||||
2026 |
3.Segment information - Geographical area
|
Second Quarter |
Asia Pacific
Africa
|
The
Americas
|
Europe |
Total |
Turnover (€ million) |
||||
2025 |
||||
2026 |
||||
Change (%) |
( |
First Half |
Asia Pacific
Africa
|
The
Americas
|
Europe |
Total |
Turnover (€ million) |
||||
2025 |
||||
2026 |
||||
Change (%) |
( |
( |
Notes to the condensed consolidated financial statements |
4.Taxation
|
5.Earnings per share
|
First Half |
||
2026 |
2025(a)
|
|
EPS – Basic |
||
Net profit attributable to shareholders’ equity (€ million) |
||
Average number of shares (millions of share units) |
||
EPS – basic (€) |
||
EPS – Basic from continuing operations |
||
Net profit from continuing operations attributable to shareholders’ equity (€ million) |
||
EPS – Basic from continuing operations (€) |
||
EPS – Basic from discontinued operations |
||
Net profit from discontinued operations attributable to shareholders’ equity (€ million) |
||
EPS – Basic from discontinued operations (€) |
||
EPS – Diluted |
||
Net profit attributable to shareholders’ equity (€ million) |
||
Adjusted average number of shares (millions of share units) |
||
EPS – diluted (€) |
||
EPS – Diluted from continuing operations |
||
Net profit from continuing operations attributable to shareholders’ equity (€ million) |
||
EPS – Diluted from continuing operations (€) |
||
EPS – Diluted from discontinued operations |
||
Net profit from discontinued operations attributable to shareholders’ equity (€ million) |
||
EPS – Diluted from discontinued operations (€) |
||
Millions |
|
Number of shares at 31 December 2025 (net of treasury shares) |
|
Shares repurchased under the share buyback programme |
( |
Net movements in shares under incentive schemes |
|
Number of shares at 30 June 2026 (net of treasury shares) |
Notes to the condensed consolidated financial statements |
6.Demerger of the Ice Cream Business
|
€ million |
First Half |
|
Total results from discontinued operations (Ice Cream) |
2026 |
2025
|
Turnover |
||
Operating (loss)/profit |
( |
|
(Loss)/Profit before tax from discontinued operations |
( |
|
Taxation |
( |
|
(Loss)/Profit after taxation from discontinued operations |
( |
|
Gain on disposal of discontinued operations |
||
Profit after taxation from discontinued operations |
||
Attributable to: |
||
Non-controlling interests |
( |
|
Shareholders’ equity |
||
Earnings per share from discontinued operations (€) |
||
Diluted earnings per share from discontinued operations (€) |
||
Notes to the condensed consolidated financial statements |
7.Acquisitions and disposals
|
Deal completion date |
Acquired/disposed business |
2 February 2026 |
Sold Graze, a healthy snacking brand in the UK to Katjes International GmbH & Co. |
12 February 2026 |
HUL acquired the remaining
based, and clean-label consumer wellness brand focused on the need spaces such as Lifestyle
Protein, Hair & Beauty Supplements and Women’s health.
|
2 March 2026 |
Unilever Indonesia disposed its tea business in Indonesia operating under the SariWangi brand
to PT Savoria Kreasi Rasa.
|
16 March 2026 |
Unilever disposed its Home Care business (powder detergents and liquids) in Central America
and the Caribbean, including the Unisola manufacturing facility in El Salvador, to Industria La
Popular (Guatemala).
|
23 March 2026 |
Sold
portfolio of local soap brands (predominantly laundry bars), to SDTM CI, Ambition International
Limited, and Aspiration Holding Limited.
|
1 April 2026 |
Sold the Group's shares in Kwality Wall’s (India) Limited (“KWIL”) to The Magnum Ice Cream Co.* |
1 April 2026 |
Sold Unilever Ice Cream Comercial, Lda. (Portugal) to The Magnum Ice Cream Company.* |
1 June 2026 |
Acquired
position in the US Greens Supplement category.
|
8.Share buyback
|
Notes to the condensed consolidated financial statements |
9.Financial instruments
|
30 June 2026 |
31 December 2025
|
30 June 2025 |
|||||||
€ million |
Current |
Non-
current
|
Total |
Current |
Non-
current
|
Total |
Current |
Non-
current
|
Total |
Cash and cash equivalents |
|||||||||
Cash at bank and in hand |
|||||||||
Short-term deposits(a)
|
|||||||||
Other cash equivalents(b)
|
|||||||||
Other financial assets |
|||||||||
Financial assets at amortised cost(c)
|
|||||||||
Financial assets at fair value through other
comprehensive income(d)
|
|||||||||
Financial assets at fair value through profit or
loss:
|
|||||||||
Derivatives |
|||||||||
Other(e)
|
|||||||||
Total financial assets(f)
|
|||||||||
Notes to the condensed consolidated financial statements |
9.Financial instruments (continued)
|
Fair value |
Carrying amount |
|||||
€ million |
As at 30
June 2026
|
As at 31
December
2025
|
As at 30
June 2025
|
As at 30
June 2026
|
As at 31
December
2025
|
As at 30
June 2025
|
Financial assets |
||||||
Cash and cash equivalents |
||||||
Financial assets at amortised cost |
||||||
Financial assets at fair value through other comprehensive
income
|
||||||
Financial assets at fair value through profit and loss: |
||||||
Derivatives |
||||||
Other |
||||||
Financial liabilities |
||||||
Bank loans and overdrafts |
( |
( |
( |
( |
( |
( |
Bonds and other loans |
( |
( |
( |
( |
( |
( |
Lease liabilities |
( |
( |
( |
( |
( |
( |
Derivatives |
( |
( |
( |
( |
( |
( |
Other financial liabilities |
( |
( |
( |
( |
( |
( |
( |
( |
( |
( |
( |
( |
|
As at 30 June 2026
|
As at 31 December 2025
|
As at 30 June 2025
|
|||||||
€ million |
Level 1 |
Level 2 |
Level 3 |
Level 1 |
Level 2 |
Level 3 |
Level 1 |
Level 2 |
Level 3 |
Assets at fair value |
|||||||||
Financial assets at fair value through other
comprehensive income
|
|||||||||
Financial assets at fair value through profit or
loss:
|
|||||||||
Derivatives(a)
|
|||||||||
Other |
|||||||||
Liabilities at fair value |
|||||||||
Derivatives(b)
|
( |
( |
( |
||||||
Contingent consideration |
( |
( |
( |
||||||
Notes to the condensed consolidated financial statements |
10.Dividends
|
Per Unilever PLC ordinary share (traded on the London Stock Exchange): |
£ |
Per Unilever PLC ordinary share (traded on Euronext in Amsterdam): |
€ |
Per Unilever PLC American Depositary Receipt: |
US$ |
Announcement
Date
|
Ex-dividend Date
for Ordinary
Shares
|
Ex-dividend Date
for ADRs
|
Record Date |
Last Date for DRIP
Election
|
Payment Date |
|
Q2 2026 Dividend
|
28 July 2026 |
06 August 2026 |
07 August 2026 |
07 August 2026 |
27 August 2026 |
18 September 2026 |
Q3 2026 Dividend
|
28 October 2026 |
12 November 2026 |
13 November 2026 |
13 November 2026 |
27 November 2026 |
18 December 2026 |
11.Events after the balance sheet date
|